A three arm, prospective study to compare the effect of six weeks exposure to the combination of lopinavir (LPVr)/Combivir (AZT [zidovudine]/3TC [lamivudine]) versus lopinavir alone or Combivir alone in HIV-negative healthy subjects on the development of abnormalities of lipid and glucose metabolism.

Trial Profile

A three arm, prospective study to compare the effect of six weeks exposure to the combination of lopinavir (LPVr)/Combivir (AZT [zidovudine]/3TC [lamivudine]) versus lopinavir alone or Combivir alone in HIV-negative healthy subjects on the development of abnormalities of lipid and glucose metabolism.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lamivudine/zidovudine; Lopinavir/ritonavir
  • Indications HIV infections
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Acronyms SAMA002
  • Most Recent Events

    • 06 Mar 2013 Pooled analysis of bone turnover markers presented at the 20th Conference on Retroviruses and Opportunistic Infections.
    • 11 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12605000661673).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top